News & Updates

In patients with stroke, administering standard-dose tenecteplase before mechanical thrombectomy is associated with a higher rate of early substantial reperfusion compared with low-dose alteplase, without compromising functional and safety outcomes, according to a study.

Once-daily oral treatment with the JAK inhibitor upadacitinib delivers clinically meaningful facial and total body repigmentation in adults and adolescents with non-segmental vitiligo, according to the phase III Viti-Up 1 and 2 trials.

Several copy number variants (CNVs) contribute to severe phenotypes in schizophrenia spectrum disorders (SSDs), and disruptions in foetal brain development are associated with poor cognition, suggests a study.

Glucose nadir and rip appear to influence both satiety and subsequent energy intake in healthy young women, independent of post-prandial fluctuations of insulin and other appetite-related gut hormones, according to a study.

Patients with Ebola virus disease (EVD) appear to experience neurological symptoms during acute infection and numerous neurological sequelae during recovery, according to a study.

Hong Kong’s first robotic-assisted, minimally invasive pelvic fracture reduction and fixation surgery has been performed by an orthopaedic team of the Chinese University of Hong Kong (CUHK). As of August 2026, three procedures have been performed, with blood loss reduced by up to 90 percent and incision size reduced by about 80 percent.

A multidomain, systematic lifestyle intervention (SLI) may yield a significantly greater improvement in global cognitive function over 2 years compared with a flexible lifestyle intervention (FLI) among older adults at high risk of dementia, according to the LatAm-FINGERS* trial presented at AAIC 2026.

Anaemia in patients with acute ischaemic stroke (AIS) is associated with an increased risk of death both in the short and long term, as shown in a local study.

Ribociclib combined with letrozole or fulvestrant demonstrates robust progression-free (PFS) and overall survival (OS), with modest objective response rates in heavily pretreated patients with advanced breast cancer, according to a real-world study.